Response to: 'COVID-19 in patients with rheumatic diseases: what is the real mortality risk?' by Marques et al

Affiliations

¹ Division of Rheumatology, Allergy, and Immunology, Harvard Medical School, Boston, Massachusetts, USA.
² Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USA.
³ Division of Rheumatology, Allergy, and Immunology, Harvard Medical School, Boston, Massachusetts, USA zswallace@partners.org.

Comment

Kristin M D'Silva et al. Ann Rheum Dis. 2022 Aug.

. 2022 Aug;81(8):e135.

doi: 10.1136/annrheumdis-2020-218431. Epub 2020 Jul 13.

¹ Division of Rheumatology, Allergy, and Immunology, Harvard Medical School, Boston, Massachusetts, USA.
² Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USA.
³ Division of Rheumatology, Allergy, and Immunology, Harvard Medical School, Boston, Massachusetts, USA zswallace@partners.org.

No abstract available

Keywords: antirheumatic agents; arthritis, rheumatoid; epidemiology; health services research.

Comment on

Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot'.
D'Silva KM, Serling-Boyd N, Wallwork R, Hsu T, Fu X, Gravallese EM, Choi HK, Sparks JA, Wallace ZS. D'Silva KM, et al. Ann Rheum Dis. 2020 Sep;79(9):1156-1162. doi: 10.1136/annrheumdis-2020-217888. Epub 2020 May 26. Ann Rheum Dis. 2020. PMID: 32457048 Free PMC article.
COVID-19 in patients with rheumatic diseases: what is the real mortality risk?
Marques C, Pinheiro MM, Reis Neto ET, Dantas AT, Ribeiro FM, Melo AKG. Marques C, et al. Ann Rheum Dis. 2022 Aug;81(8):e134. doi: 10.1136/annrheumdis-2020-218388. Epub 2020 Jul 13. Ann Rheum Dis. 2022. PMID: 32660978 No abstract available.